<DOC>
	<DOCNO>NCT01965600</DOCNO>
	<brief_summary>An endotoxin challenge administer healthy subject induce production inflammatory marker . An investigational drug placebo administer prior endotoxin challenge assess effect investigational drug marker inflammation . Safety tolerability also assess .</brief_summary>
	<brief_title>A Study To Evaluate The Safety And Effects On The Body Of An Investigational Drug Using An Endotoxin-Induced Inflammatory Response Model</brief_title>
	<detailed_description>The trial terminate 25 March 2015 due safety concern regard administration endotoxin uncertain availability future endotoxin lot .</detailed_description>
	<criteria>Healthy men woman ( nonchildbearing potential ) age 1840 year . Body Mass Index ( BMI ) 1830 kg/m2 total body weight &gt; 50 kg ( 110 lb ) . History evidence habitual use tobacco nicotinecontaining product within 3 month screen . History frequent headache migraine ( &gt; 3 per month ) , headaches absence caffeine . Caffeine consumption excess 3 cup per day . Subjects experience cold/flu symptom ( ie , runny nose , cough , and/or fever ) within 2 week first administration study drug/placebo period . History recurrent chronic infection type tuberculosis , sinusitis , urinary tract infection , respiratory tract dental ( abscess ) infection , etc . Also exclude subject recurrent oral genital herpes , recurrent herpes zoster , infection otherwise judge investigator potential worsening enrol study . Treatment LPS past 12 month and/or history allergic type reaction know hypersensitivity endotoxin time .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Endotoxin challenge</keyword>
</DOC>